Why the study?
How does platelet thrombus formation correlate with agonist-inducible platelet aggregation and platelet-monocyte aggregates in cardiac patients receiving aspirin or dual antiplatelet therapy?
Population
72 subjects, including 33 healthy controls, 20 cardiac patients receiving aspirin monotherapy, and 19…
Comparison
Aspirin monotherapy or dual antiplatelet therapy vs Healthy controls
Design
Cross-sectional
Authors
Loading...
May guide therapy-specific platelet monitoring in cardiac patients; leaves open whether AUC 10 predicts clinical outcomes.
How does platelet thrombus formation correlate with agonist-inducible platelet aggregation and platelet-monocyte aggregates in cardiac patients receiving aspirin or dual antiplatelet therapy?
Residual platelet thrombogenicity in aspirin-treated patients is associated with collagen-induced platelet aggregation, whereas in patients receiving dual antiplatelet therapy it is predominantly dependent on ADP-induced platelet aggregation.
Hosokawa et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: